Ensuring Responsible and Ethical Use of AI Technology
In this part of his Pharmaceutical Executive video interview, Brice Challamel, Vice President, AI Products & Platforms, Moderna, discusses how Moderna is ensuring responsible and ethical use of AI technology within its operations.
Coverage for GLP-1 Drugs for Obesity is in Flux | AHIP 2024
Coverage for GLP-1 agonist drugs is in a state of flux, Timothy Law, DO, MBA, chief medical officer of Highmark Inc., said in an interview with Managed Healthcare Executive before the annual AHIP meeting in Las Vegas. Law — along with panelists Melanie R. Jay, M.D., director of NYU Langone Comprehensive Program on Obesity Research, and Amy Meister, D.O., chief medical officer of WeightWatchers — spoke about how GLP-1 therapies are changing how the healthcare industry views prevention and treatment.
Establishing a Data Ecosystem Using Automation to Optimize Regulatory-Compliant Clinical Trials
Significant advances in technology are providing new opportunities to collect and utilize real-world data to establish better clinical trial protocols that have a patient-centric focus and the ability to transform healthcare. However, it is important to understand how such applications work and their impact on safety.
This webcast series uncovers the concerns of safety professionals and other stakeholders involved in the development and implementation of clinical trial protocols in the digital era and highlights methods to best apply digital data into routine practice to best optimize trial success and adhere to strict regulatory guidance.
Novo Nordisk Threatens Lego’s Position as Denmark’s No. 1 Brand
Denmark’s Lego A/S has long reigned as the country’s most valuable brand, but the toymaker is now under threat of being toppled by Novo Nordisk A/S, whose weight-loss treatments have become a global pop culture phenomenon.
IQVIA announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting.
AllazoHealth CEO William Grambley and other industry leaders weighed in on the topic of “Combining RWE and AI to Bend the Adherence Curve” with Suzanne Shelley (she/her) for this month’s Pharmaceutical Commerce Magazine.
“The goal is to use today’s advanced modeling technology to better understand the complex relationships between patient-level characteristics, adherence-related behaviors, and health outcomes, and then use the data-driven insights to deliver individual level outreach, making them patient-specific (not generalized) to improve outcomes,” says William Grambley, CEO, AllazoHealth.
To read the full article, visit https://lnkd.in/gkxCfxst
#RWE #healthcareAI #medicationadherence
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs